Home Other Building Blocks H-Asn(glcnac-beta-d)-oh

H-Asn(glcnac-beta-d)-oh

CAS No.:
2776-93-4
Catalog Number:
AG00C46J
Molecular Formula:
Molecular Weight:
Pack Size
Purity
Availability
Location
Price(USD)
Quantity
  
25mg
≥ 99% (TLC)
1 week
United States
$374
- +
Product Description
Catalog Number:
AG00C46J
Chemical Name:
H-Asn(glcnac-beta-d)-oh
CAS Number:
2776-93-4
MDL Number:
MFCD02259695
IUPAC Name:
(2S)-4-[[(2R,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]amino]-2-amino-4-oxobutanoic acid
InChI:
InChI=1S/C12H21N3O8/c1-4(17)14-8-10(20)9(19)6(3-16)23-11(8)15-7(18)2-5(13)12(21)22/h5-6,8-11,16,19-20H,2-3,13H2,1H3,(H,14,17)(H,15,18)(H,21,22)/t5-,6+,8+,9+,10+,11+/m0/s1
InChI Key:
YTTRPBWEMMPYSW-HRRFRDKFSA-N
Properties
Complexity:
460  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
6  
Defined Bond Stereocenter Count:
0
Exact Mass:
335.133g/mol
Formal Charge:
0
Heavy Atom Count:
23  
Hydrogen Bond Acceptor Count:
9  
Hydrogen Bond Donor Count:
7  
Isotope Atom Count:
0
Molecular Weight:
335.313g/mol
Monoisotopic Mass:
335.133g/mol
Rotatable Bond Count:
6  
Topological Polar Surface Area:
191A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
-5.7  
Literature
Title Journal
The potential investment impact of improved access to accelerated approval on the development of treatments for low prevalence rare diseases. Orphanet journal of rare diseases 20110101
Early initiation of enzyme replacement therapy improves metabolic correction in the brain tissue of aspartylglycosaminuria mice. Journal of inherited metabolic disease 20101001
Bilateral pulvinar signal intensity decrease on T2-weighted images in patients with aspartylglucosaminuria. Acta radiologica (Stockholm, Sweden : 1987) 20080701
The structural basis of the difference in sensitivity for PNGase F in the de-N-glycosylation of the native bovine pancreatic ribonucleases B and BS. Biochemistry 20080318
Sleep disturbances in aspartylglucosaminuria (AGU): a questionnaire study. Journal of inherited metabolic disease 20061001
Reduction in head size in patients with aspartylglucosaminuria. Acta neurologica Scandinavica 20051101
Massive accumulation of Man2GlcNAc2-Asn in nonneuronal tissues of glycosylasparaginase-deficient mice and its removal by enzyme replacement therapy. Glycobiology 20050101
Five-year follow-up of two siblings with aspartylglucosaminuria undergoing allogeneic stem-cell transplantation from unrelated donors. Transplantation 20040815
Startle epilepsy complicating aspartylglucosaminuria. Brain & development 20040301
Angiokeratoma corporis diffusum in a Spanish patient with aspartylglucosaminuria. The British journal of dermatology 20021001
Glycosylasparaginase activity requires the alpha-carboxyl group, but not the alpha-amino group, on N(4)-(2-Acetamido-2-deoxy-beta-D-glucopyranosyl)-L-asparagine. Archives of biochemistry and biophysics 20010715
Human leukocyte glycosylasparaginase: cell-to-cell transfer and properties in correction of aspartylglycosaminuria. FEBS letters 20010615
Synthesis of N4-(2-acetamido-2-deoxy-beta-D-glucopyranosyl)-L-asparagine analogues. n-Butyramide, 3-chloropropionamide, 3-aminopropionamide, and isovaleramide analogues. Carbohydrate research 20010423
Co-existence of lysosomal storage diseases in a consanguineous family. Child: care, health and development 20010301
Glycosylasparaginase inhibition studies: competitive inhibitors, transition state mimics, noncompetitive inhibitors. Journal of enzyme inhibition 20010101
Properties